Clinical Trial

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

Name: Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) — clinical trial record (NCT07340723)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: GVHD

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for grade II acute GVHD (graft-versus-host disease )

Trial Details

NCT Number	NCT07340723
Lead Sponsor	Daihong Liu
Conditions	GVHD,Acute, Stem Cell Transplant Complications
Enrollment	168 participants
Start Date	2025-06-01
Primary Completion	2027-06-01 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-14